Tissue-type plasminogen activator (t-PA), tissue-type plasminogen activator inhibitor (t-PAI), and other factors (platelets, fibrinogen, fibrinogen degrada tion products, antithrombin-III, plasminogen, and α2-plasmin inhibitor [α2-PI]) related to the fibrinolytic system were studied in 21 patients undergoing total joint replacement.
Seventeen of the 21 patients revealed an impaired fibrinolytic activity from the first to seventh postoperative day and a subsequent return to the preopera tive level by the fourteenth postoperative day. There were accompanying increases in the level of α2-PI and in the t-PAI/t-PA ratio, and there was decrease in plas minogen level. Such hypofibrinolytic states may be related to a higher incidence of postoperative thrombosis in total joint replacement patients.
Get full access to this article
View all access options for this article.
References
1.
Redell N., Balazs EA: Effect of intraarticular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clin Orthoped Rel Res80:25-31, 1971.
2.
Kikuchi H., Tanaka S., Matsuo O.: Plasminogen activator in synovial fluid from patients with rheumatoid arthritis . J Rheumatol14:439-445, 1987.
3.
Matsuo O., Tanaka S., Kikuchi H.: Effect of urinary trypsin inhibitor on osteoarthritis. Thromb Res52:237-245, 1988.
4.
Kikuchi H., Tanaka S., Matsuo O.: Effects of protease inhibitors on plasminogen activator and collagenase in the synovial fluid of rheumatoid arthritis. Med Sci Res16:855-856, 1988.
5.
Kakkar VV: The diagnosis of deep vein thrombosis using the 125I-fibrinogen test . Arch Surg104:152-159, 1972.
6.
Sevitt S.: Venous thrombosis and pulmonary embolism: Their prevention by oral anticoagulant . Am J Med33:703-716, 1962.
7.
Muller R., Musikic P.: Hemorheology in surgery. Angiology38:581-592, 1987.
8.
Mellbring G. , Dahlgren S., Reiz S., et al: Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery . Throm Res32:574-584, 1983.
9.
Knight MT, Dawson R., Melrose DG: Fibrinolytic response to surgery. Lancet8034:370-373, 1977.
10.
Mansfield AO : Alteration in fibrinolysis associated with surgery and venous thrombosis. Br J Surg59:754-757, 1972.
11.
Russell ME, Quertermous T., Declerck PJ, et al: Binding of tissue-type plasminogen activator with human endothelial cell monolayers: Characterization of the high affinity interaction with plasminogen activator inhibitor-1. J Biol Chem265:2569-2575, 1990.
12.
Fukao H., Ueshima S., Tanaka N., et al: Suppression of plasminogen activator inhibitor 1 release by fibrin from human umbilical vein endothelial cells. Thromb Res57 (Suppl 10): 11-20, 1990.
13.
Markus G.: The relevance of plasminogen activators to neoplasmic growth. Enzyme40:158-172, 1988.
14.
Harke H., Gennrich M.: Aprotinin-ACD-blood: Experimental studies on the effect of aprotinin on the plasmatic and thrombotic coagulation. Anaesthhetist29:266-276, 1980.
15.
Tilsner V., Greul W.: Thrombolytic therapy: Agents, indication, clinical performance, and side effects . Vasc Surg13:79-86, 1979.
16.
Matsuo O., Rijken DC, Collen D.: On the thrombolytic properties of human tissue type plasminogen activator and urokinase. In: Urokinase: Basic and Clinical Aspects, ed. by Mannucci PM, D angelo A. London: Academic Press, 1982, pp 55-61.
17.
Matsuo O., Sakai T., Bando H., et al: Plasminogen activator in bronchoalveoar fluid. Hemostasis16:43-50, 1986.
18.
Mahmoud M., Gaffiney PJ: Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH). Throm Haemost53:356-359, 1985.
19.
Aoki N., Moroi M., Matsuda M., et al: The behavior of α2-plasmin inhibitor in fibrinolytic states. J Clin Invest60:361-369, 1977.
